At present, multiple biotherapeutics, directed against cytokines such as TNF, IL‐17, IL‐12/IL‐23 and IL‐36, have been approved or are in development for the treatment of psoriasis, as well as other inflammatory conditions. This evidence concerns the gene IL17A and psoriasis.